Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

UBS Global Wealth Management said it now has an attractive view on U.S. equities, supported in part by growing adoption of ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

However, though the target market is expected to undergo significant growth, factors like stringent cholesteryl isostearate ...